Javascript must be enabled to continue!
Improving Access for Patients Undergoing Gonadotoxic Therapy: Creation of a Formal Fertility Preservation Program [25A]
View through CrossRef
INTRODUCTION:
Prior to 2016, patients undergoing gonadotoxic therapies were not routinely directed towards educational resources regarding fertility preservation options. In 2016, a formalized fertility preservation program was initiated to increase education, referrals, and provide treatment options to this uniquely vulnerable patient population.
METHODS:
A database was created following initiation of the fertility preservation program (FPP) to track patient demographics such as diagnosis, treatment plan, referring department, consultation turn-around time, uptake of fertility preservation services, and outcomes (post treatment and post fertility preservation, if applicable). For patients undergoing sperm/oocyte/embryo cryopreservation for fertility preservation needs prior to program initiation (2006–2015), a chart review was performed to obtain the same data. We assessed the overall impact of implementation of FPP as compared to other published data from institutions providing formal fertility preservation services.
RESULTS:
Each year following implementation of FPP, noted statistically significant increase in referrals, consultations, and uptake of fertility preservation services. Similarly, the referring departments and diagnoses on referral expanded beyond oncologic providers and oncologic diagnoses, respectively. We also noted a trend of increased uptake for female patients for fertility preservation as compared to male patients, which is dissimilar from previously published data.
CONCLUSION:
A formalized program for fertility preservation improves access and uptake of services for patients undergoing gonadotoxic therapies. Our program demonstrated significant beneficial impact on multiple parameters of interest, even within the first two years following implementation. Subsequently, fertility preservation for oncology patients is now considered a covered benefit within this health maintenance organization.
Ovid Technologies (Wolters Kluwer Health)
Title: Improving Access for Patients Undergoing Gonadotoxic Therapy: Creation of a Formal Fertility Preservation Program [25A]
Description:
INTRODUCTION:
Prior to 2016, patients undergoing gonadotoxic therapies were not routinely directed towards educational resources regarding fertility preservation options.
In 2016, a formalized fertility preservation program was initiated to increase education, referrals, and provide treatment options to this uniquely vulnerable patient population.
METHODS:
A database was created following initiation of the fertility preservation program (FPP) to track patient demographics such as diagnosis, treatment plan, referring department, consultation turn-around time, uptake of fertility preservation services, and outcomes (post treatment and post fertility preservation, if applicable).
For patients undergoing sperm/oocyte/embryo cryopreservation for fertility preservation needs prior to program initiation (2006–2015), a chart review was performed to obtain the same data.
We assessed the overall impact of implementation of FPP as compared to other published data from institutions providing formal fertility preservation services.
RESULTS:
Each year following implementation of FPP, noted statistically significant increase in referrals, consultations, and uptake of fertility preservation services.
Similarly, the referring departments and diagnoses on referral expanded beyond oncologic providers and oncologic diagnoses, respectively.
We also noted a trend of increased uptake for female patients for fertility preservation as compared to male patients, which is dissimilar from previously published data.
CONCLUSION:
A formalized program for fertility preservation improves access and uptake of services for patients undergoing gonadotoxic therapies.
Our program demonstrated significant beneficial impact on multiple parameters of interest, even within the first two years following implementation.
Subsequently, fertility preservation for oncology patients is now considered a covered benefit within this health maintenance organization.
Related Results
Fertility preservation and fertility treatment in transgender adolescents and adults in a Swedish region, 2013–2018
Fertility preservation and fertility treatment in transgender adolescents and adults in a Swedish region, 2013–2018
Abstract
STUDY QUESTION
In a transgender population referred for fertility consultation, which factors influence the decision to...
Navigating fertility dilemmas across the lifespan in girls with Turner syndrome—a scoping review
Navigating fertility dilemmas across the lifespan in girls with Turner syndrome—a scoping review
Abstract
BACKGROUND
Girls with Turner syndrome (TS) lack a partial or complete sex chromosome, which causes an accelerated decli...
L26/O-090 Bridging the knowledge-to-action gap: formal training as the primary driver of fertility preservation referrals. Across-sectional study
L26/O-090 Bridging the knowledge-to-action gap: formal training as the primary driver of fertility preservation referrals. Across-sectional study
Abstract
Study question
What are the levels of knowledge and guideline awareness regarding fertility preservation among I...
Abstract PO4-11-11: Provider perceptions of the POSITIVE trial, endocrine therapy interruption, and fertility preservation
Abstract PO4-11-11: Provider perceptions of the POSITIVE trial, endocrine therapy interruption, and fertility preservation
Abstract
Background: Fertility preservation and family planning are pressing survivorship concerns for many young, reproductive-aged women with hormone receptor-posi...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
How to Co-Create: A Compendium of Methods for Co-Creating Solutions to Complex and Wicked Problems in Public Health
How to Co-Create: A Compendium of Methods for Co-Creating Solutions to Complex and Wicked Problems in Public Health
Background: Co-creation has become a vital approach in public health, engaging diverse stakeholders, including vulnerable and marginalized populations, to collaboratively design an...
P-404 Sexual function, psychological distress, and remaining fertility in female cancer survivors
P-404 Sexual function, psychological distress, and remaining fertility in female cancer survivors
Abstract
Study question
How many women after fertility preservation and gonadotoxic treatment suffer from sexual dysfunction und...
Abstract P4-04-15: Oncofertility and Breast Cancer: An Analysis of Perception and Practices Among Specialists
Abstract P4-04-15: Oncofertility and Breast Cancer: An Analysis of Perception and Practices Among Specialists
Abstract
Introduction: Worldwide, breast cancer is considered the most common cancer among women, with advanced treatments improving survival chances. In this contex...

